What is mRNA technology and how does it work?

mRNA stands for messenger RNA. It is a tiny set of genetic instructions that tells your body's cells how to produce a specific protein — for example, a protein that looks like part of a virus. Your immune system then learns to recognise and fight that protein. If you later encounter the real virus, your body is already prepared. Unlike traditional vaccines, mRNA does not alter your DNA — it simply delivers a temporary message to your cells. The message breaks down naturally after doing its job.

What does FDA approval mean and why does it matter for investors?

The FDA — the U.S. Food and Drug Administration — is the government body responsible for ensuring medicines and vaccines are safe and effective before they can be sold to the public. When the FDA approves a product, it is a major commercial milestone. It means the company can now legally sell that product in the United States, one of the world's largest healthcare markets. For investors, FDA approval can significantly boost a company's revenue potential and signal that other products in its pipeline could follow a similar path.

What is a value chain and why does this group include more than just biotech companies?

A value chain is the series of steps and organisations involved in bringing a product from idea to end user. For an mRNA vaccine, that journey includes scientists designing the therapy, manufacturers producing the ingredients, specialist companies handling cold storage and logistics, and clinical organisations running the safety trials. This group includes companies at every stage of that chain — not just the headline biotech firms — because each link plays a critical role in making mRNA medicines a commercial reality.

What are lipid nanoparticles and why are they important for mRNA vaccines?

Lipid nanoparticles are tiny fat-based particles that act as a protective shell for mRNA molecules. On their own, mRNA strands are fragile and would break down before reaching your cells. Lipid nanoparticles wrap around the mRNA and safely deliver it inside the body. They are a foundational piece of mRNA vaccine technology, which is why companies specialising in this area — such as Alnylam Pharmaceuticals — are included in this investment group.

What is cold-chain logistics and why does it matter for mRNA vaccines?

Cold-chain logistics refers to the process of keeping temperature-sensitive products — like mRNA vaccines — properly refrigerated or frozen throughout their entire journey, from the factory to the patient. mRNA vaccines can be damaged if they get too warm, so maintaining the right temperature at every step is essential. Companies that provide the equipment and infrastructure for this process play a vital, behind-the-scenes role in making mRNA medicines accessible at scale.

What does 'growth-oriented' mean when describing an investment theme?

A growth-oriented investment theme focuses on companies that are expanding rapidly or operating in fast-moving industries, rather than businesses that deliver slow, steady, predictable returns. These companies often reinvest their profits into research, development, and scaling up — meaning short-term returns can be more unpredictable. The potential upside can be greater, but so can the risk. It is a style of investing suited to those who are comfortable with some uncertainty in exchange for the possibility of stronger long-term gains.

What is genomic sequencing and why is it relevant to mRNA vaccines?

Genomic sequencing is a scientific process used to read and map the genetic code of a virus or organism. For mRNA vaccines, this is particularly important because viruses like the flu mutate over time — meaning the vaccine needs to be updated regularly to remain effective. Companies like Illumina provide the sequencing technology that allows scientists to quickly identify new viral variants and design updated vaccine formulations to match them.

14 Handpicked stocks

mRNA Vaccines: Could Non-COVID Markets Drive Growth?

The FDA has granted its first-ever approval for an mRNA seasonal flu vaccine, moving the groundbreaking technology beyond its pandemic origins. This regulatory milestone creates compelling investment opportunities across innovative biotechnology firms and the specialized supply chains that support them.

Jamie Dutta | Financial Market Analyst

Published on August 7

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

MODERNA INC

MRNA

Current Price

$59.17

As a pioneer in mRNA technology, it is at the forefront of developing and commercialising mRNA seasonal flu vaccines.

Pfizer

PFE

Current Price

$26.76

A major pharmaceutical leader with deep investments in mRNA capabilities and vast global vaccine distribution networks.

BIONTECH SE SPON ADS EACH REP 1 ORD SHS

BNTX

Current Price

$93.67

A leading mRNA biotechnology firm rapidly expanding its prophylactic vaccine pipeline to target seasonal infectious diseases like the flu.

NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1

NVO

Current Price

$47.26

Thermo Fisher Scientific

TMO

Current Price

$594.00

SANOFI SPON ADR ECH REP 0.5 ORD SHS

SNY

Current Price

$43.46

Join Nemo FREE today and unlock every stock

It only takes 60 seconds.

Why You'll Want to Watch These Stocks

🧬

A Technology That Just Got Its Biggest Stamp of Approval

The FDA's first-ever approval of an mRNA flu vaccine is a turning point — not just for one company, but for an entire generation of genetic medicines. The question now is: which companies are best placed to benefit?

📈

The Pipeline Is Just Getting Started

With flu vaccines leading the way, mRNA technology is being applied to a growing list of diseases and conditions. Analysts are watching this space closely, and the commercial opportunities could be significant.

🔗

The Whole Ecosystem, Not Just One Bet

This isn't just about one biotech stock. Every mRNA vaccine needs specialised manufacturers, cold-chain logistics, and genomic tools to work — and this group covers them all, giving you broader exposure to the revolution.

Your Basket's Financial Footprint

This basket's $1.11T total market cap is concentrated in several very large-cap constituents, giving it a generally stable profile. Large-cap dominance tends to anchor returns and reduce idiosyncratic volatility versus smaller-cap baskets.

Key Takeaways for Investors:

Large-cap dominance generally implies lower volatility and more stable returns, with performance tracking broader market trends.
Suitable as a core portfolio holding for diversified exposure, not as a speculative, high-risk trade.
Expect steady, long-term value rather than rapid, short-term gains; growth is likely moderate.

Total Market Cap

MRNA: $22.46B
PFE: $147.11B
BNTX: $23.16B
Other

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.

If you invested across these assets:

≈

In 12 months it might be worth:

$1,000.00

+65.43%

≈

About This Group of Stocks

Our Expert Thinking

The FDA's approval of the first mRNA seasonal flu vaccine is a landmark moment. It proves that messenger RNA technology is no longer just a pandemic tool — it's a platform with lasting commercial potential. This group captures the full opportunity: from the biotech firms pioneering new treatments to the specialist manufacturers and logistics companies that make it all possible.

What You Need to Know

This is a growth-oriented theme, meaning the companies here are focused on innovation and expansion rather than steady, established returns. The basket spans a broad ecosystem — including biotech developers, contract manufacturers, cold-chain logistics providers, and genomic sequencing firms — so it reflects the full supply chain behind advanced therapeutics, not just one company or one product.

Why These Stocks

Each stock was carefully selected by professional analysts to represent a meaningful piece of the mRNA value chain. From pioneers like Moderna and BioNTech to essential enablers like Thermo Fisher and Vertiv, these picks were chosen because of their strategic positioning, pipeline potential, and role in scaling the next generation of genetic medicines. Nothing here was picked at random.

Group Performance Snapshot

65.43%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 65.43% over the next year.

10 of 14

Stocks Rated Buy by Analysts

10 of 14 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Berkshire Capital Pivot: Which Businesses Could Gain?

With new leadership at the helm, Berkshire Hathaway is actively shrinking its record cash pile through accelerated buybacks and substantial new equity investments. This strategic shift offers investors a compelling reason to examine the high-quality, cash-generating businesses that align with the conglomerate's evolving portfolio strategy.

Aerospace Deliveries (China Regulatory Lift) Surge

Following the resolution of a regulatory bottleneck in China, Airbus saw its May deliveries jump 59% year-over-year. This clearing of the backlog signals renewed momentum for global aerospace manufacturing and presents opportunities for aviation suppliers and component makers.

Liquid Alternatives: Could Private Market Caps Shift Flows?

Blackstone and Partners Group recently capped investor withdrawals from specific private equity funds, highlighting the growing liquidity concerns within alternative investments. This shift creates a compelling opportunity for publicly traded asset managers and liquid alternative funds as investors redirect capital toward more accessible financial instruments.

mRNA Vaccines: Could Non-COVID Markets Drive Growth?

Top Picks from This Group

Why You'll Want to Watch These Stocks

A Technology That Just Got Its Biggest Stamp of Approval

The Pipeline Is Just Getting Started

The Whole Ecosystem, Not Just One Bet

Your Basket's Financial Footprint

12 Month Growth Potential

About This Group of Stocks

Our Expert Thinking

What You Need to Know

Why These Stocks